↓ Skip to main content

Dupilumab in the management of moderate-to-severe asthma: the data so far

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter
9 tweeters
patent
5 patents

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dupilumab in the management of moderate-to-severe asthma: the data so far
Published in
Therapeutics and Clinical Risk Management, September 2017
DOI 10.2147/tcrm.s125964
Pubmed ID
Authors

Pilar Barranco, Elsa Phillips-Angles, Javier Dominguez-Ortega, Santiago Quirce

Abstract

Severe asthma constitutes illness in a relatively small proportion of all patients with asthma, but it is a major public health problem - with considerable effect on morbidity, mortality, as well as a high burden on health care resources. Regardless of effective treatments being widely available and the existence of treatment guidelines, a large population of severe asthma cases remain uncontrolled. Achieving and maintaining asthma control in this group of patients is, therefore, of utmost importance. The recognition of distinct inflammatory phenotypes within this population has driven the development of targeted biological therapies - particularly, selective targeted monoclonal antibodies (mAbs). It is noteworthy that in approximately 50% of these patients, there is strong evidence of the pathogenic role of T helper type-2 (Th2) cytokines, such as interleukin (IL)-4 and IL-13, orchestrating the eosinophilic and allergic inflammatory processes. Among the recently developed antiasthma biologic drugs, the mAb dupilumab is very promising given its ability to inhibit the biological effects of both IL-4 and IL-13. In this review, we focused on IL-4 and IL-13, as these interleukins are considered to play a key role in the pathophysiology of asthma, and on dupilumab, an anti-IL-4 receptor human mAb, as a forthcoming treatment for uncontrolled severe asthma in the near future.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 76 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 16%
Researcher 11 14%
Other 8 11%
Student > Postgraduate 7 9%
Student > Bachelor 7 9%
Other 14 18%
Unknown 17 22%
Readers by discipline Count As %
Medicine and Dentistry 29 38%
Biochemistry, Genetics and Molecular Biology 7 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Agricultural and Biological Sciences 4 5%
Immunology and Microbiology 4 5%
Other 7 9%
Unknown 21 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2022.
All research outputs
#2,054,681
of 22,805,349 outputs
Outputs from Therapeutics and Clinical Risk Management
#90
of 1,263 outputs
Outputs of similar age
#41,985
of 315,645 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 29 outputs
Altmetric has tracked 22,805,349 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,263 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,645 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.